Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2016-08-23 Annual Report
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
FY16 Results Presentation 22 pages 7.9MB
Annual Report Classification · 95% confidence The document is titled 'Full-Year Results for FY16' and dated 24 August 2016, indicating it covers a full fiscal year financial performance. It includes detailed financial results such as revenue, expenses, net loss, cash burn, and R&D tax incentives. The content also covers achievements, pipeline updates, patent portfolio, and milestones for the next fiscal year. The document is comprehensive, with substantive financial data and analysis, not merely an announcement or summary. It is a detailed presentation of the company's annual financial results and business overview for the fiscal year 2016. This matches the definition of an Annual Report (10-K) or a detailed financial report covering the full fiscal year. However, since it is titled as 'Full-Year Results' and structured as a presentation rather than a formal statutory annual report, it aligns best with an Annual Report (10-K) category in this classification context, as it provides a full financial performance overview for the year. The document length (14,788 characters) supports it being a full report rather than a brief announcement or presentation only. FY 2016
2016-08-23 English
Date of AGM 1 page 134.3KB
AGM Information Classification · 95% confidence The document is a short announcement dated 9 August 2016 from Regeneus Ltd regarding the date and location of its 2016 Annual General Meeting (AGM). It states the meeting will be held on 19 October 2016 and that a formal notice will be sent later. There is no detailed AGM material or presentation included, only a notification of the meeting date. The document length is only 532 characters, indicating it is a brief notice rather than the AGM report or materials themselves. According to the rules, such a notice about the AGM date is classified as AGM Information (AGM-R).
2016-08-08 English
Response to ASX Price Query 5 pages 429.3KB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX Compliance to Regeneus Ltd regarding a price query about unusual trading activity in the company's securities. It requests information about any undisclosed material information that could explain the price and volume changes, references ASX Listing Rules (3.1, 3.1A, 17.1, 18.7), and discusses potential trading halts. The document is a regulatory inquiry and compliance request rather than a financial report, earnings release, or announcement of results. It does not contain financial data or company performance information. It is a regulatory filing related to market compliance and disclosure obligations under ASX rules.
2016-08-04 English
European patent to grant on stem cell secretions for acne 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the granting of a European patent for a stem cell secretions technology related to acne treatment. It discusses the patent details, commercial rights, and company background. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory filings. The content is a corporate announcement about intellectual property rights, not a financial report or regulatory filing. Given the nature and length of the document (2711 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2016-07-31 English
Appendix 4C - Quarterly 6 pages 519.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly results for the period ended 30 June 2016' and includes detailed financial data such as cash flows, operating cash flow figures, and a consolidated statement of cash flows. It references the Appendix 4C, which is a standard quarterly cash flow report for entities admitted on the basis of commitments, commonly used in Australian regulatory filings. The document contains substantive financial data for the quarter and year to date, including cash flow from operating, investing, and financing activities. The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2016
2016-07-28 English
Q2 2016 Update 4 pages 915.4KB
Interim / Quarterly Report Classification · 75% confidence The document is titled 'Regeneus Ltd ­ Q2 2016 Update' and is dated 7/1/2016. It is a newsletter style update covering the quarter ended 30 June 2016. The content includes updates on partnering opportunities, clinical trial progress, research grants, and industry reports. It does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). Instead, it provides a narrative update on business developments and research progress. The length is 6387 characters, which is relatively short and consistent with a newsletter or update rather than a full financial report. There is no indication that this is a formal earnings release or regulatory filing. Given these characteristics, the document best fits the category of an Interim / Quarterly Report (IR) as it provides substantive updates for a fiscal quarter period, even though it is more narrative than financial. The confidence is moderate due to the narrative style but the quarterly update nature is clear. Q2 2016
2016-06-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.